OCCULT hepatitis B virus infection may be associated with a distinctive blood gene expression signature, with MMP9 emerging as a potential biomarker for identifying patients at risk of liver injury, according to an exploratory transcriptomic analysis.
The findings followed a clinical case involving rapid progression from genotype C occult hepatitis B infection to advanced hepatocellular carcinoma, highlighting the need for improved risk stratification.
Occult Hepatitis B Presents Diagnostic Challenges
Occult hepatitis B virus infection is characterised by undetectable hepatitis B surface antigen despite detectable viral DNA, creating challenges for identifying and monitoring affected patients.
Currently, validated biomarkers for predicting liver injury or disease progression in this population remain unavailable.
Researchers reported a patient with genotype C occult hepatitis B infection who rapidly developed advanced hepatocellular carcinoma.
This case prompted an exploratory investigation into potential molecular markers associated with occult infection.
The researchers reanalysed a publicly available transcriptomic dataset containing peripheral blood mononuclear cell samples from individuals with occult hepatitis B and healthy controls.
Differential gene expression analysis was performed to identify candidate biomarkers, followed by sensitivity testing to assess the consistency of the findings.
MMP9 Expression Distinguishes Occult Hepatitis B Samples
The analysis identified 1,930 differentially expressed genes between the occult hepatitis B and control groups.
Among these, MMP9, which encodes matrix metalloproteinase 9, demonstrated one of the strongest transcriptional signals (log₂ fold change: 10.69; adjusted p=6.13×10⁻³⁶).
All five occult hepatitis B samples expressed MMP9 at substantially higher levels than the five healthy controls.
Raw expression counts ranged from 547–25,598 in the infection group, compared with 2–8 among controls, with no overlap between groups.
Exploratory receiver operating characteristic analysis demonstrated complete separation (area under the curve: 1.000), with sensitivity and specificity both reaching 100% (95% CI: 56–100% for each).
However, these estimates were derived from only 10 samples and require cautious interpretation.
Biomarker Findings Require Prospective Validation
Sensitivity analyses further supported the consistency of the MMP9 transcriptional signal.
Across 10 leave-one-out iterations, MMP9 remained among the highest-ranked genes, with consistently increased expression (log₂ fold change: 10.52–10.81).
The mean number of differentially expressed genes across these analyses was 1,901, with a coefficient of variation of 5%.
Researchers suggested that MMP9 could represent an early-warning candidate biomarker for occult hepatitis B-related liver injury.
Nevertheless, the study did not establish that MMP9 predicts future hepatocellular carcinoma, and the small discovery cohort limits generalisability.
The findings also require validation in independent populations before clinical risk assessment applications can be considered.
Overall, the analysis identified a promising molecular signal that warrants prospective investigation to determine its relationship with liver injury and disease progression in occult hepatitis B infection.
Reference
Liu X et al. Occult Hepatitis B Virus Genotype C Infection with Rapid Progression to Advanced Hepatocellular Carcinoma: A Clinical Case and Exploratory Transcriptomic Analysis Identifying MMP9 as an Early-Warning Candidate Biomarker,” be used for publication. Diag Micro Infec Dis. 2026.